Zhifei Biotech announced that the quadrivalent influenza virus lysis vaccine developed by Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has obtained a drug clinical trial approval notice from the State Drug Administration and agreed to carry out clinical trials to prevent influenza caused by vaccine-related influenza viruses.

Zhitongcaijing · 10/25 11:41
Zhifei Biotech announced that the quadrivalent influenza virus lysis vaccine developed by Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has obtained a drug clinical trial approval notice from the State Drug Administration and agreed to carry out clinical trials to prevent influenza caused by vaccine-related influenza viruses.